Indaptus Therapeutics Stock (NASDAQ:INDP)
Previous Close
$0.89
52W Range
$0.84 - $3.10
50D Avg
$1.17
200D Avg
$1.81
Market Cap
$11.27M
Avg Vol (3M)
$114.63K
Beta
1.13
Div Yield
-
INDP Company Profile
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
INDP Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ABVC | ABVC BioPharma, Inc. |
| KPRX | Kiora Pharmaceuticals, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| LGVN | Longeveron Inc. |
| REVB | Revelation Biosciences, Inc. |
| NTRB | Nutriband Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| VRAX | Virax Biolabs Group Limited |
| ASMB | Assembly Biosciences, Inc. |
| RNXT | RenovoRx, Inc. |
| RZLT | Rezolute, Inc. |
| TPST | Tempest Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| FBRX | Forte Biosciences, Inc. |